Dexmedetomidine Reduces Atrial Fibrillation After Adult Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials

AbstractBackgroundDexmedetomidine has been shown to have antiarrhythmic effects by exhibiting sympatholytic properties and activating the vagus nerve in preclinical studies. Results from clinical trials of dexmedetomidine on atrial fibrillation (AF) following adult cardiac surgery are controversial.Materials and methodsWe searched EMBASE, PubMed and Cochrane CENTRAL databases for randomized controlled trials (RCTs) comparing the antiarrhythmic effect of dexmedetomidine versus placebo or other anesthetic drugs in adult patients undergoing cardiac surgery. The primary outcome was the incidence of AF. The secondary outcomes were ventricular arrhythmias [ventricular fibrillation (VF), ventricular tachycardia (VT)], mechanical ventilation (MV) duration, intensive care unit (ICU) length of stay, and hospital length of stay, and all-cause mortality.ResultsThirteen trials with a total of 1684 study patients were selected. Compared with controls, dexmedetomidine significantly reduced the incidence of postoperative AF [odds ratio (OR) 0.75; 95% confidence interval (CI) 0.58 –0.97;P = 0.03] and VT (OR 0.23; 95% CI 0.11 –0.48;P
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research

Related Links:

In this study, ECGs were evaluated before and after the usage of salbutamol and ipratropium bromide. Patients were evaluated before and after 4 weeks of treatment :1) salbutamol, 90 mcg 1 puffs every 4 hours 2) Ipratropium Bromide, 34 mcg 2 puffs every 6 hours. ECGs performed pre-treatment and at 4th Week. We were able to find various arrhythmias such as atrial tachycardia, atrial fibrillation and ventricular tachycardia. 60 ECGs recordings in 30 treated patients (M=F). Out of 30 patients, ECG changes recorded in 28 patients. The most common met ECG was with atrial tachycardia in 20 patients out of which 12 were females (6...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway pharmacology and treatment Source Type: research
Conclusions: Episodes of malignant arrhythmias are frequent in patients with OSA and systolic ventricular dysfunction. Although it is not possible to identify risk factors for the development of these events, its intensity depend on the systemic inflammatory level determined by IL2 and C-reactive protein.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Sleep and control of breathing Source Type: research
Review in-depth clinical information, latest medical news, and guidelines about cardiac arrhythmias, including atrial fibrillation, paroxysmal tachycardia, ventricular tachycardia, and ventricular fibrillation. Read about diagnostic tests for arrhythmia and arrhythmia management.
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Resource Center Source Type: news
ConclusionsArrhythmias, including clinically significant abnormal rhythms, were common. Tachyarrhythmias were more frequent during dialysis and the immediate postdialytic period. The relevance of these findings to clinical outcomes requires additional study.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
BioSig Technologies and Mayo Clinic have joined forces once again, this time to develop a new product pipeline to support some of the more advanced features of BioSig's Pure EP System. Samuel Asirvatham, MD, Mayo Clinic's vice-chair of innovation and medical director of the electrophysiology (EP) laboratory, will lead the new development program. The company previously signed a 10-year collaboration agreement with Mayo Clinic in March 2017. "The new product that we intend to develop under the latest licensing will seek to significantly advance the current arrhythmia treatments," said Kenne...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Publication date: Available online 4 September 2019Source: Pharmacological ResearchAuthor(s): Enrico Paolini, Giulia Stronati, Federico Guerra, Alessandro CapucciAbstractOver the last 35 years, flecainide proved itself one of the most commonly used arrhythmic drugs, expanding its original indication for ventricular arrhythmias and results nowadays as the cornerstone of the rhythm control strategy in atrial fibrillation management of patients without structural heart disease. While the increased mortality associated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) still casts his shadow over flecainide cli...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
AbstractDespite major therapeutic advances over the last decades, complex supraventricular and ventricular arrhythmias (VAs), particularly in the emergency setting or during revascularization for acute myocardial infarction (AMI), remain an important clinical problem. Although the incidence of VAs has declined in the hospital phase of acute coronary syndromes (ACS), mainly due to prompt revascularization and optimal medical therapy, still up to 6% patients with ACS develop ventricular tachycardia and/or ventricular fibrillation within the first hours of ACS symptoms. Despite sustained VAs being perceived predictors of wors...
Source: Europace - Category: Cardiology Source Type: research
ConclusionsDue to worse outcomes with arrhythmias, there is a need for better screening and follow-up of ESLD patients for dysrhythmias.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Background: The prevalence of atrial fibrillation (AF) has not been well described in young patients with inherited heart diseases such as the inherited cardiomyopathies: hypertrophic cardiomyopathy (HCM), familial dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular non-compaction (LVNC); or inherited arrhythmia syndromes including long QT syndrome (LQTS), Brugada syndrome (BrS) or catecholaminergic polymorphic ventricular tachycardia (CPVT).
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: 455 Source Type: research
Stereotaxis, a company that has developed robotic magnetic navigation technology to deliver catheters to the heart during ablation procedures, is introducing its latest generation system. The new Stereotaxis Genesis RMN platform features smaller magn...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Radiology Source Type: blogs
More News: Anesthesia | Anesthesiology | Arrhythmia | Atrial Fibrillation | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Databases & Libraries | Heart | Intensive Care | Study | Ventricular Tachycardia